Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy.
OBJECTIVE
To assess the prevalence of oesophagitis, Barrett's oesophagus (BE) and other oesophageal mucosal abnormalities in patients with systemic sclerosis (SSc) without prior selection on digestive clinical presentation. We also investigated the association between oesophageal endoscopic and manometric data with clinical manifestations of SSc.


METHODS
Oesophageal endoscopy and manometry were performed in 133 consecutive patients with SSc, receiving proton pump inhibitor (PPI) therapy since SSc diagnosis.


RESULTS
Endoscopy revealed oesophagitis in 43 patients (32.3%), BE in 9 patients (6.8%), candidiasis in 7 patients (5.3%) and hyperplastic polyp arising in ectopic gastric mucosa in 1 patient. Patients with severe oesophageal motor impairment further exhibited a higher prevalence of interstitial lung disease (ILD) when compared with those without.


CONCLUSIONS
Our study underlines the high frequency of oesophageal mucosal abnormalities in unselected SSc patients receiving long-term PPI therapy. A relationship between oesophagitis/BE and severe manometric motor disturbances was established; these patients may require a higher regimen of PPI. Finally, our series indicates a correlation between severe oesophageal motor disturbances and evidence for ILD in patients, suggesting that gastro-oesophageal reflux may be one of the contributing factors of ILD in SSc; this subgroup of patients may require close monitoring of lung parameters.
Marie
I
I
Department of Internal Medicine, Rouen University Hospital, Rouen Cedex, France. isabelle.marie@chu-rouen.fr
Ducrotte
P
P
Denis
P
P
Hellot
M F
MF
Levesque
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004941:Esophagitis / Q000139:chemically induced*; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism*; D005764:Gastroesophageal Reflux / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000009:adverse effects; D012595:Scleroderma, Systemic / Q000188:drug therapy*
D054328:Proton Pump Inhibitors; D017494:Proton Pumps